Author:
de Boer R. A.,Nijenkamp L. L. A. M.,Silljé H. H. W.,Eijgenraam T. R.,Parbhudayal R.,van Driel B.,Huurman R.,Michels M.,Pei J.,Harakalova M.,van Lint F. H. M.,Jansen M.,Baas A. F.,Asselbergs F. W.,van Tintelen J. P.,Brundel B. J. J. M.,Dorsch L. M.,Schuldt M.,Kuster D. W. D.,van der Velden J.,
Abstract
AbstractIn 2011 the Netherlands Heart Foundation allocated funding (CVON, Cardiovasculair Onderzoek Nederland) to stimulate collaboration between clinical and preclinical researchers on specific areas of research. One of those areas involves genetic heart diseases, which are frequently caused by pathogenic variants in genes that encode sarcomere proteins. In 2014, the DOSIS (Determinants of susceptibility in inherited cardiomyopathy: towards novel therapeutic approaches) consortium was initiated, focusing their research on secondary disease hits involved in the onset and progression of cardiomyopathies. Here we highlight several recent observations from our consortium and collaborators which may ultimately be relevant for clinical practice.
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献